Taiwan Biotech gets FDA warning letter over quality-control issues

fda
An FDA inspector uncovered problems with the drugmaker’s quality-control unit in September 2017. (FDA)

The FDA issued Taiwan Biotech a warning letter, citing a number of issues with the company’s quality-control unit.

In a letter posted on the regulatory agency’s website, the FDA said an inspector uncovered problems with the Taiwanese drugmaker’s quality-control unit during an inspection of the plant in early September 2017. It said the company didn’t provide an adequate system for monitoring environmental conditions in aseptic processing areas.

Taiwan Biotech, which was founded in 1945, produces drugs for the treatment of cardiovascular, diabetic, respiratory and eye care disease, according to its website.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

During the inspection, the FDA found “numerous samples lacked basic documentation, including missing colony-forming unit (CFU) counts and the identity of the person who collected the sample,” the agency wrote, adding that a microbiology technician failed to collect required surface samples.

Additionally, Taiwan Biotech was cited for not following an adequate written testing program designed to assess the stability characteristics of drug products, and for failing to keep written records for the evaluation of the quality standards of each drug it produces in order to track drug product specifications and manufacturing and control procedures.

“Significant findings in this letter indicate that your quality unit is not able to fully exercise its authority and/or responsibilities,” the FDA wrote. “Your firm must provide the quality unit with appropriate authority and sufficient resources and staff to carry out its responsibilities and consistently ensure drug quality.”

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.